title: Risk factors for venous port migration in a single institute in Taiwan.
abstract: BACKGROUND
  An implantable port device provides an easily accessible central route for long-term chemotherapy. Venous catheter migration is one of the rare complications of venous port implantation. It can lead to side effects such as pain in the neck, shoulder, or ear, venous thrombosis, and even life-threatening neurologic problems. To date, there are few published studies that discuss such complications.
  
  
  METHODS
  This retrospective study of venous port implantation in a single center, a Taiwan hospital, was conducted from January 2011 to March 2013. Venous port migration was recorded along with demographic and characteristics of the patients.
  
  
  RESULTS
  Of 298 patients with an implantable import device, venous port migration had occurred in seven, an incidence rate of 2.3%. All seven were male and had received the Bard port Fr 6.6 which had smaller size than TYCO port Fr 7.5 and is made of silicon. Significantly, migration occurred in male patients (P = 0.0006) and in those with lung cancer (P = 0.004). Multivariable logistic regression analysis revealed that lung cancer was a significant risk factor for port migration (odds ratio: 11.59; P = 0.0059). The migration rate of the Bard port Fr 6.6 was 6.7%. The median time between initial venous port implantation and port migration was 35.4 days (range, 7 to 135 days) and 71.4% (5/7) of patients had port migration within 30 days after initial port implantation.
  
  
  CONCLUSIONS
  Male sex and lung cancer are risk factors for venous port migration. The type of venous port is also an important risk factor.
authors.forename: Wen-Chieh
authors.initials: WC
authors.lastname: Fan
authors.forename: Cheng-Han
authors.initials: CH
authors.lastname: Wu
authors.forename: Ming-Ju
authors.initials: MJ
authors.lastname: Tsai
authors.forename: Ying-Ming
authors.initials: YM
authors.lastname: Tsai
authors.forename: Hsu-Liang
authors.initials: HL
authors.lastname: Chang
authors.forename: Jen-Yu
authors.initials: JY
authors.lastname: Hung
authors.forename: Pei-Huan
authors.initials: PH
authors.lastname: Chen
authors.affiliation: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 68 ChungHwa 3rd Road, Cianjin District, Kaohsiung City 80145, Taiwan. chjeya@cc.kmu.edu.tw.
authors.forename: Chih-Jen
authors.initials: CJ
authors.lastname: Yang
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan; D020246:Venous Thrombosis / Q000209:etiology*